Carvedilol administration (3.125 mg twice daily for 1 week) significantly reduced ROS generation by polymorphonuclear leukocytes from 314 to 185 mV (P<0.025) in normal subjects.
Normal subjects
Carvedilol vs Baseline (3.125 mg twice daily)
ROS generation by polymorphonuclear leukocytes and mononuclear cells, p=<0.025
Background —The purpose of this study was to test whether carvedilol has an antioxidant effect in humans in vivo. Methods and Results —We administered 3.125 mg of carvedilol twice daily to normal subjects for 1 week. ROS generation by polymorphonuclear leukocytes and mononuclear cells fell from 314±183.43 and 303±116 mV to 185±157 and 189±63 mV ( P <0.025), respectively. m -Tyrosine fell from 4.24±0.99 to 4.03±0.97 ng/mL ( P =0.01), and o -tyrosine fell from 4.59±1.10 to 4.24±0.99 ng/mL ( P =0.004) in the absence of a change in phenylalanine concentrations. Conclusions —We conclude that carvedilol significantly inhibits ROS generation by leukocytes and oxidative conversion of phenylalanine to m - and o -tyrosine.
Building similarity graph...
Analyzing shared references across papers
Loading...
Paresh Dandona
Rajaram Karne
Husam Ghanim
Circulation
University at Buffalo, State University of New York
Building similarity graph...
Analyzing shared references across papers
Loading...
Dandona et al. (Tue,) conducted a other in Normal subjects. Carvedilol vs. Baseline was evaluated on ROS generation by polymorphonuclear leukocytes and mononuclear cells (p=<0.025). Carvedilol administration (3.125 mg twice daily for 1 week) significantly reduced ROS generation by polymorphonuclear leukocytes from 314 to 185 mV (P<0.025) in normal subjects.
www.synapsesocial.com/papers/6a091d694c1e2db30bd257ef — DOI: https://doi.org/10.1161/01.cir.101.2.122
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: